Onco Actu du 25 octobre 2017

	1. Biologie
Cancer biology still needs physicists [Nature] Considering game theory and the role of physical forces could lead to better treatments for cancer, says Robert Austin.
	2.6 Etiologie - Environnement
Glyphosate in the Age of Stupid [The Risk-Monger] Somehow a substance with a toxicity level below that of ingredients found in biscuits, chocolate and coffee is responsible not only for the potential risk of a rare type of cancer to farmers applying glyphosate, but it is now unanimously declared to be the main cause of autism, cancer, obesity, leaky gut, celiac and any allergy consumers may be suffering from.
IARC rejects false claims in Reuters article (“In glyphosate review, WHO cancer agency edited out “non-carcinogenic” findings”) [IARC] IARC will not respond to baseless, defamatory statements about IARC or its Working Group, whether these are issued by Monsanto or other interested parties, directly or through third parties, including media contacts.
	3.1.1 Prévention - Tabac - e-cigs
MPs launch inquiry into e-cigarettes over fears they could 're-normalise' smoking for teens [The Telegraph] “We want to understand where the gaps are in the evidence base, the impact of the regulations, and the implications of this growing industry on NHS costs and the UK's public finances."
E-cigarettes: Cross-party group of MPs launches inquiry [BBC News] The science and technology committee will look at their effectiveness as a stop-smoking tool and the impact of their growing use on health.
Swapping Cigarettes for Vaping [The Scientist] New evidence suggests e-cigarettes are not without risks to human health, but can be useful in getting people to kick their smoking habit.
	3.6 Prévention - Activité physique
Walking below minimum recommended levels linked to lower mortality risk [ACS] Investigators say walking has potential to significantly improve public’s health.
	4.10 Dép., diag. & prono. - FDA, EMA, NICE,...
Statement from FDA Commissioner Scott Gottlieb, M.D., on new steps to advance medical device innovation and help patients gain faster access to beneficial technologies [FDA] To make the development process more efficient and predictable, the FDA is also releasing three new guidance documents today related to medical devices.
	4.7 Dép., diag. & prono. - Col de l'utérus
Previous screening results important for smear-test decision after age 60 [Karolinska Institutet] Being screened again after the age of 60 reduces the risk of cervical cancer in women who have previously had abnormal smear tests and in women who did not have smear tests in their 50s, researchers at Karolinska Institutet show.
	5. Traitements
Proton Therapy Lowers Treatment Side Effects in Pediatric Head and Neck Cancer Patients [Penn Medicine] Penn, CHOP study finds treatment is just as effective as photon radiation while improving quality of life.
Actually, Many New Cancer Drugs May Be Helpful And Worth Trying [Forbes] The authors of that study and an accompanying editorial highlighted the absence of evidence that most drugs approved in Europe through 2013 improve quality-of-life. But that information was absent does not mean that new cancer agents don’t improve patients’ well-being or cause net harm.
Internal radiotherapy: tackling cancer from within [Cancer Research UK] Internal radiotherapy comes in two main forms: brachytherapy and liquid therapy. Brachytherapy, which literally means ‘short-range therapy’, gets up-close and personal with cancer through a radioactive source that’s placed next to the tumour via surgery. Whereas radioactive liquid therapy homes in on cancer via the bloodstream.
	5.12 Immunothérapies
When Hope Runs Out, Cancer Patients Are Making Their Own DIY Immunotherapy Treatments [Gizmodo] This month, Jo and the husband of another lung cancer patient were among those that published a DIY guide to cancer vaccines online: “How to make and treat yourself with a peptide vaccine targeting the EGFR T790M mutation.”
	5.12.1 Immunothérapies - partenariats
Incyte grabs a new PD-1 checkpoint drug in $900M deal with MacroGenics [EndPoints] Incyte is widely viewed as the leader in the IDO1 field now, with pivotal data coming up for epacadostat. Already partnered with Merck and Bristol-Myers Squibb in combination trials using their checkpoint, Incyte clearly sees value in having their own checkpoint to use for combos.
	5.12.7 Immunothérapies - vaccins
Viral Vector Mobilan Offers a New Approach for Cancer Immunotherapy [Roswell Park Cancer Institute] Preclinical study in prostate cancer shows that virus-based drug candidate may improve anticancer vaccination.
	5.2.3 Pharma - économie
What’s driving the rapid growth of the top 20 biopharma companies in the world? [EndPoints] Rare diseases and oncology will remain a central focus in R&D.
	5.4 Traitements - Economie
Celgene takes its most aggressive price hikes yet on Revlimid, Pomalyst: analyst [FiercePharma] Defying critics in Congress and elsewhere, Celgene hiked the list prices of key cancer meds Revlimid and Pomalyst by 9% this month, taking their cumulative increases for the year to nearly double the range that many Big Pharma peers have pledged to avoid.
	6. Lutte contre les cancers
The Transformation Of Medical Education From Choosing More To Choosing Wisely [Health Affairs Blog] Patients can be harmed by too much care, just as when they receive too little care. Until recently, the former danger had been largely overlooked.
	6.4 Médico-éco
Robotic-assisted surgery: more expensive, but not always more effective [Reuters] ”The rapid increase in costly robot surgery in lieu of laparoscopic surgery without a definite advantage for the patient is a problem that can be applied not only to the urological field but also to the entire surgical field.”
	6.9 Controverses
French scientists in uproar over changes to medical-research clusters [Nature] Biomedical-research agency accused of attempting to undermine autonomy of university–hospital groups.